Sign Out
No formal pharmacokinetic drug interaction studies have been conducted with Pembrolizumab (KEYTRUDA). Since pembrolizumab is cleared from the circulation through catabolism, no metabolic drug-drug interactions are expected.
The use of systemic corticosteroids or immunosuppressants before starting Pembrolizumab (KEYTRUDA) should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of Pembrolizumab (KEYTRUDA). However, systemic corticosteroids or other immunosuppressants can be used after starting Pembrolizumab (KEYTRUDA) to treat immune-mediated adverse reactions [see Precautions]. Corticosteroids can also be used as premedication, when Pembrolizumab (KEYTRUDA) is used in combination with chemotherapy, as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.
